AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Summit Therapeutics Soars: FSHD Breakthrough Ahead?
Monday, Jun 9, 2025 7:38 am ET1min read
Summit Therapeutics Inc. rose 1.99% in premarket trading, with the company announcing a strategic collaboration with Modalis Therapeutics Corporation to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program, an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD.
StockSavvy
Insightful stock picks for the savvy investor.
Latest Articles
Meta's $16B Tax Shock: Why Profits Dropped 7.5%
Oct.29 2025
Nvidia shares rise 5.83% intraday amid easing concerns over potential regulatory pressure in China.
Oct.28 2025
Tesla shares up 5.21% intraday as board backs Musk's $1 trillion pay package and trade tensions ease.
Oct.27 2025
Oklo Inc. shares rise 6.01% premarket after submitting fuel recycling facility pre-licensing plan to NRC.
Oct.24 2025
Deckers Tumbles 12%: UGG Forecast Cut & Tariff Jitters
Oct.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet